2022
De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report
Gandhi S, Klein J, Robertson AJ, Peña-Hernández MA, Lin MJ, Roychoudhury P, Lu P, Fournier J, Ferguson D, Mohamed Bakhash SAK, Catherine Muenker M, Srivathsan A, Wunder EA, Kerantzas N, Wang W, Lindenbach B, Pyle A, Wilen CB, Ogbuagu O, Greninger AL, Iwasaki A, Schulz WL, Ko AI. De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report. Nature Communications 2022, 13: 1547. PMID: 35301314, PMCID: PMC8930970, DOI: 10.1038/s41467-022-29104-y.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 infectionVirologic responsePersistent SARS-CoV-2 infectionResistance mutationsPre-treatment specimensB-cell deficiencyRemdesivir resistanceRemdesivir therapyViral sheddingCase reportAntiviral agentsPatientsCombinatorial therapyInfectionTherapyWhole-genome sequencingTreatmentImportance of monitoringDe novo emergenceFold increaseRNA-dependent RNA polymeraseNovo emergencePotential benefitsMutationsIndolent
2016
Transfusion support for the oncology patient
Schulz W, Snyder E. Transfusion support for the oncology patient. 2016, 574-580. DOI: 10.1002/9781119013020.ch50.ChaptersOncology patientsTransfusion supportTransfusion-transmitted diseasesSafety of transfusionTA-GVHDTransplant patientsAdverse eventsDonor testingAppropriate therapyABO incompatibilityPatient populationTransfusion therapyOncologic disordersMajor therapyPatientsTransfusion servicesCellular antigensBlood componentsTherapyFrequent exposureTransfusionSpecific assessmentRiskAlloimmunizationImmunomodulation